DelveInsight’s, “Pediatric Brain Tumors Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pediatric Brain Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Pediatric Brain Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Pediatric Brain Tumors Pipeline Outlook
Key Takeaways from the Pediatric Brain Tumors Pipeline Report
- In May 2025, University of Florida announced the studies that RNA liposomes activate APCs, induce antigen-specific T cell immunity, and can supplant DCs in a cell therapy model for HGG and have shown feasibility and activity of this approach in preclinical models and in canine patients with a spontaneous malignant glioma. In one arm of this study, we will investigate the safety and immunologic activity of RNA-LP vaccines in pediatric patients with recurrent pHGG.
- In May 2025, GlaxoSmithKline conducted a study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants.
- In May 2025, St. Jude Children’s Research Hospital organized studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not adequate to identify actual risk of recurrence. In order to address this, we will stratify medulloblastoma treatment in this phase II clinical trial based on both clinical risk (low, standard, intermediate, or high risk) and molecular subtype (WNT, SHH, or Non-WNT Non-SHH).
- DelveInsight’s Pediatric Brain Tumors Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Pediatric Brain Tumors treatment.
- Promising Pediatric Brain Tumors Companies such as Biodexa Pharmaceuticals, Cellectar Biosciences, ZIOPHARM Oncology, Y-mAbs Therapeutics Inc., Neonc Technologiesd Inc. and others.
- The leading Pediatric Brain Tumors Pipeline Therapies such as Doxorubicin, temozolomide, thalidomide, tozuleristide, plerixafor, CX 4945, Abemaciclib and others.
Stay ahead with the most recent pipeline outlook for Pediatric Brain Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pediatric Brain Tumors Treatment Drugs
Pediatric Brain Tumors Emerging Drugs Profile
- MTX110: Biodexa Pharmaceuticals
MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD) that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumor. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favorable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG and recurrent medulloblastoma and preclinical for treatment of glioblastoma. MTX110 is delivered directly into and around the patient’s tumor via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumor to very high drug concentrations while simultaneously minimizing systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumor cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines. Currently, the drug is in Phase I/II stage of its development for the treatment of diffuse intrinsic pontine glioma.
- Iopofosine: Cellectar Biosciences
Iopofosine is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. Iopofosine is currently being evaluated in the CLOVER-WaM Phase II pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM), a Phase IIb study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase I study for a variety of pediatric cancers. The U.S. Food and Drug Administration granted iopofosine Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) have been granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. The European Commission granted an ODDs for r/r MM and WM. Currently, the drug is in Phase I stage of its development for the treatment of pediatric brain tumor.
The Pediatric Brain Tumors Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Pediatric Brain Tumors with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pediatric Brain Tumors Treatment.
- Pediatric Brain Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Pediatric Brain Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pediatric Brain Tumors market
Explore groundbreaking therapies and clinical trials in the Pediatric Brain Tumors Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Pediatric Brain Tumors Drugs
Pediatric Brain Tumors Companies
Biodexa Pharmaceuticals, Cellectar Biosciences, ZIOPHARM Oncology, Y-mAbs Therapeutics Inc., Neonc Technologiesd Inc. and others.
Pediatric Brain Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Pediatric Brain Tumors Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Unveil the future of Pediatric Brain Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pediatric Brain Tumors Market Drivers and Barriers
Scope of the Pediatric Brain Tumors Pipeline Report
- Coverage- Global
- Pediatric Brain Tumors Companies- Biodexa Pharmaceuticals, Cellectar Biosciences, ZIOPHARM Oncology, Y-mAbs Therapeutics Inc., Neonc Technologiesd Inc. and others.
- Pediatric Brain Tumors Pipeline Therapies- Doxorubicin, temozolomide, thalidomide, tozuleristide, plerixafor, CX 4945, Abemaciclib and others.
- Pediatric Brain Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Pediatric Brain Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Pediatric Brain Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Pediatric Brain Tumors Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Pediatric Brain Tumors: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Pediatric Brain Tumors – DelveInsight’s Analytical Perspective
- Drug profiles in the detailed report…..
- Late Stage Products (Phase III)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- MTX110: Biodexa Pharmaceuticals
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Pediatric Brain Tumors Key Companies
- Pediatric Brain Tumors Key Products
- Pediatric Brain Tumors- Unmet Needs
- Pediatric Brain Tumors- Market Drivers and Barriers
- Pediatric Brain Tumors- Future Perspectives and Conclusion
- Pediatric Brain Tumors Analyst Views
- Pediatric Brain Tumors Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pediatric-brain-tumors-pipeline-insight